Loading
Kraig Biocraft Laboratories, Inc Stock: price and insider trades · United States
Kraig Biocraft Laboratories, Inc: what insiders have been doing
This page follows insider dealings at Kraig Biocraft Laboratories, Inc as filed with SEC (Form 4), a company from the Chemicals & Materials sector. Kraig Biocraft Laboratories, Inc has had no insider filing for more than a year; the last one goes back to 29 May 2025.
Looking back to 2021, when coverage begins, insiders filed no purchases and 64 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Culp Inc and Gold.com, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
67
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
64 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.09
Analyst consensus
Income statement
EBITDA-US$3M
Net income-US$3.6M0.0% margin
Valuation
Beta1.58
Balance sheet & cash
Market capUS$99.4M
Total debtUS$1.7M
Free Cash Flow-US$1.8M
Profitability & ownership
ROA-89.8%
% insiders18.6%
% institutions0.0%
Last declaration on 29 May 2025
Declarations67 total
314,636 shares@ US$0.0828100.0% of flowClass A Common StockSEC:0001641172-25-012897:0
27,500 shares@ US$0.090630.6% of flowCommon StockSEC:0001641172-25-003638:0
62,500 shares@ US$0.090669.4% of flowCommon StockSEC:0001641172-25-003260:0
50,000 sharesCommon StockSEC:0001493152-22-020038:0
50,000 sharesCommon StockSEC:0001493152-22-019832:0
11,500 sharesCommon StockSEC:0001493152-22-019444:0
100,000 sharesCommon StockSEC:0001493152-22-019177:0
20,000 sharesCommon StockSEC:0001493152-22-019012:0
20,000 sharesCommon StockSEC:0001493152-22-018805:0
20,000 sharesCommon StockSEC:0001493152-22-018386:0
50,000 sharesCommon StockSEC:0001493152-22-018110:0
80,000 sharesCommon StockSEC:0001493152-22-017718:0
180,000 sharesCommon StockSEC:0001493152-22-017598:0
100,000 sharesCommon StockSEC:0001493152-22-017382:0
10,000 sharesCommon StockSEC:0001493152-22-017173:0
20,000 sharesCommon StockSEC:0001493152-22-016459:0
10,500 sharesCommon StockSEC:0001493152-22-016182:0
20,000 sharesCommon StockSEC:0001493152-22-015845:0
30,000 sharesCommon StockSEC:0001493152-22-015609:0
30,000 sharesCommon StockSEC:0001493152-22-015366:0
20,000 sharesCommon StockSEC:0001493152-22-015044:0
15,048 sharesCommon StockSEC:0001493152-22-014805:0
20,000 sharesCommon StockSEC:0001493152-22-014493:0
20,000 sharesCommon StockSEC:0001493152-22-013860:0
10,000 sharesCommon StockSEC:0001493152-22-013052:0
25 of 67 declarations
About Kraig Biocraft Laboratories, Inc
Kraig Biocraft Laboratories, Inc. (ticker: KBLB) is a U.S.-based biotechnology and advanced materials company headquartered in Ann Arbor, Michigan, United States. The company was founded in 2006 and has built its identity around the development and commercialization of recombinant spider silk fibers produced through genetically engineered silkworms. From an equity perspective, it is important to note that KBLB is quoted on the OTCQB market rather than NYSE or NASDAQ at this stage, even though its investor communications are framed for the broader U.S. public equity market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1413119/000149315226013630/form10-k.htm?utm_source=openai))
Kraig’s core business is the creation of high-performance biomaterials that aim to bridge the gap between laboratory innovation and industrial-scale textile production. The company develops proprietary transgenic silkworm strains and production methods designed to generate naturally spun recombinant spider silk, which it positions as a next-generation fiber platform for technical textiles, performance apparel, protective applications, and other specialty-material uses. Management describes Kraig as a pioneer in the field and highlights its role in creating some of the first transgenic silkworms capable of producing recombinant spider silk, as well as its early scientific disclosures in peer-reviewed literature. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1413119/000149315226013630/form10-k.htm?utm_source=openai))
Read moreShow less
Historically, the company’s development path has combined U.S.-based research and engineering with a gradually expanding international production footprint. Kraig has emphasized its Michigan research headquarters while also building production and commercialization capabilities in Southeast Asia, particularly Vietnam. Its public filings and company materials reference collaboration with academic and institutional partners, including the University of Notre Dame and Vietnamese sericulture-related organizations, underscoring an approach that links materials science, biological engineering, and agricultural-scale manufacturing. ([kraiglabs.com](https://www.kraiglabs.com/kraig-biocraft-laboratories-begins-scale-up-of-second-generation-dragon-silk/?utm_source=openai))
In competitive terms, Kraig occupies a niche position in a potentially large but still emerging market for high-value technical fibers. The company is differentiated by its vertically integrated spider-silk platform and by its attempt to industrialize a material that has long been viewed as scientifically promising but difficult to scale. That said, it remains an early-stage commercial story: execution risk, financing needs, and the challenge of translating production milestones into repeatable revenue generation remain central investment considerations. ([kraiglabs.com](https://www.kraiglabs.com/spider-silk-company/?utm_source=openai))
Recent developments have been materially focused on scale-up. In 2025, Kraig announced the addition of a second production facility, three advanced spider-silk strains, and a controlled-diapause production system. It later reported a first successful parallel two-facility production cycle, which it said establishes a model for continuous supply-chain output. In April 2026, the company disclosed a record month of more than 1.3 metric tons of spider-silk cocoons, a fivefold increase versus its previous high, and in March 2026 it announced a new production rearing center to support further scale-up. These milestones suggest meaningful operational progress, although investors should still treat the business as a speculative small-cap development story rather than a mature industrial compounder. ([kraiglabs.com](https://www.kraiglabs.com/kraig-biocraft-laboratories-announces-second-production-facility-three-advanced-spider-silk-strains-and-new-diapausing-system/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
